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Abstract: Tumour necosis factor alpha (TNF-o:) is
known to be involved in pathogenesis of acute renal
allograft rejection. However, measurement of cyto-
kine serum levels alone are not a reliable index of
acute rejection episodes. TNF-o: induces the release
of soluble receptors (TNF-SR55 and TNF-SR75) that
have an inhibitory activity and catabolized by the
kidney.
Twenty nine transplant recepients were studied and
compared to ten healthy controls. TNF-o:, TNF-SR55
and TNF-SR75 were measured before and after renal
transplantation. The mean pre-transplantation values
were 26.3 ± 9.7 pg/ml, 28.2 ± 8.3 and 42.5 ± 11.1
ng/ml respectively. According to post-transplant
course patients were divided into 3 groups. Group I
(stable transplant group: no= 17): The mean level of
TNF-o: value was 7.5 ± 4.6 pg/ml, TNF-SR55 6.4 ±
4.7 and TNF-SR75 12.5 ± 8 ng/ml (p NS). Group Il
(acute allograft rejection group: no = 8): The mean
values were 37.2 ± 16.2 pg/ml, 16.9 ± 9.6 and 30.9 ±
13.4 ng/ml respectively (p< 0.05). Group III cyclo-
sporine (CS) nephrotoxicity group: no= 4): The mean
level of TNF-o: was 9.9 ± 2.1 pg/ml with a highly
significant increase in its receptor values (9.4 ± 1.0 &
21.2 ± 6.8 ng/ml; vs 5.5 ± 1.2 & 12.4 ± 4.8 ng/ml
respectively (P< 0.0 I).
To improve the predictive value of this cytokine and
its receptors,we calculated the ratios of TNF-o: to
both receptors (SR55-SR75).
During acute rejection episode, the ratio values to
control were 2.4 ± 0.6 vs 1.4 ± 0.7 and 1.3 ± 0.5 vs
0.7 ± 0.4 respectively (P<O.OI).
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However, these ratios did not change significantly
from control group during CS nephrotoxicity 1.5 ±
0.5 vs 2.0 ± 0.7 and 0.5 ± 0.3 vs 0.9 ± 0.2
respectively (p>0.05). Thus, TNF-o: and its soluble
receptor levels might be of diagnostic value in renal
allograft rejecion.
In conclusion: 1) TNF-o: and its soluble receptors are
highly increased during hemodialysis. 2) There is no
significant difference between healthy controls and
patients with stable grafts. 3)There is highly signifi-
cant increase of TNF-o: and its receptors during
acute rejection episodes and the day (R-2) pre-
rejection in contrast to internal controls. 4) There is
insignificant decrease of TNF-o: during CS
nephrotoxicity with highly significant increase of
TNF-SR55, TNF-SR75 when compared to internal
controls. 5) The ratios of TNF-o: lo SR55 & SR75
showed highly significant increase during acute
rejection episodes and insignifi-cant decrease during
CS nephrotoxicity when compared to internal
controls.
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Introduction
Allograft biopsy remains the standard method for
diagnosis of acute rejection. However, this proceed-
ure always carries a risk. Thus it might be of great
value to have a non-invasive diagnostic modality.
Cytokines released early in immune cell activation
appear promising in this respect [7,15].
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The macrophage cytokine tumour necrosis factor
alpha (TNF-a.) is released in relatively large amounts
early during immune activation process [13] and is
readily detected in the circulation [4,14]. It expresses
its biological activity by triggering specific receptors
on a variety of different cells including monocytes,
lymphocytes, endothelial cells, fibroblasts and
mesangial cells [8,10). Therefore, it may be an early
marker of immune activation.
Two cellular TNF receptors have been specified.
Brockhaus (1990) and Dembic (1990), defined them
as soluble TNF receptors, namely 55 KDa (TNF-
SR55) and 75 KDa (TNF-SR75). Their plasma half-
life is longer than that of TNF-a.. It is easier to
measure these soluble receptors in serum and may
constitute a more reliable parameter than TNF-a.
itself [7].
In this study, we evaluated the reliability of serum




This study included 29 patients (21 males and 8
females) with mean age 34.1 years (range: 19-51
years). All had end stage renal disease and were on
regular haemodialysis treatment for a mean duration
of 18.4 months (range: 3-72 months). Aetiologicaly,
end stage renal disease (ESRD) was due to: chronic
glomerulonephritis in 21, polycystic kidney disease
in 3 and bilateral multiple renal stones in 5 patients.
All recipients had their first successful living renal
transplantation (Tx) at the National Institute of
Urology and Nephrology during the period from
January, 1995- April, 1997. Patients with intercurrent
infections or with known chronic inflammatory
diseases were excluded. The immunosuppressive
regimen was either imuran and prednisolone in 17 or
imuran, cyclosporine A (CSA) and prednisolone in
12 patients (Table I).
Controls
This group included ten healthy individuals (7 males
and 3 females) of comparable age.
Blood collection and techniques
• Blood samples were taken one day before trans-
plantation (day-I) and daily during the period of
post-operative hospitalization (day+ 1,+2, etc.).
• Sera were stored at -70°C for cytokine assay.
• Concomitantly, estimation of serum creatinine
(every day) and whole CSA levels (every third
day) were done.
• TNF-a. and its soluble receptors were measured
by enzyme linked immunosorbent assay (ELISA-
Medgenix Diagnostics S.A., Fleurus, Belgium) in
sera collected on the following days:
I. Sera of all patients (no.29) were analysed the
day before Tx (day-I),
2. Group I (patients with stable graft function:
no= 17): samples were analysed at day + 15.
1. Group II (patients with acute allograft
rejection: no=8) samples were analysed at
days of stable graft function (internal
controls), 2 days pre-rejection (R-2) and at the
peak of acute rejection episode (Ra).
4. Group III (patients with cyclosporine nephro-
toxicity: no=4): Sera were analysed at days of
stable graft function (internal controls) and
when CSA nephrotoxicity was diagnosed.
Statistical analysis
Statistical analysis was performed using student's-t
test for the independent groups and paired-t test for
matched groups. The level of significance was set at
p value < 0.05. All values were expressed as means ±
standard deviation.
Results
According to the post-operative course, patients were
divided into three groups (Table I):
Group l. Stable transplant group
Comprised 17 patients (12 males and 5 females) of
mean age 34.1 years. There was no acute rejection
episodes or CS-A nephrotoxicity during the period of
the study (one month postoperative). The mean serum
creatinine was 1.3 mg/dl.
Group II. Acute allograft rejection group
Comprised 8 patients (5 males and 3 females) of
mean age 33.9 years. These patients had at least one
acute rejection episode. Their mean serum creatinine
value was 4.0 mg/dl during the episode.
Group II/. Cyclosporin nephrotoxicity group
Comprised 4 male patients, of mean age 36.0 years.
Cyclosporine nephrotoxicity was defined as prog-
ressive deterioration of renal function associated with
high blood level of CSA in absence of any other
cause e.g. obstruction or rejection and which
improved after reduction of CSA dose.
Renal allograft recipients were monitored before and
during posttransplant peroid (Figure I and 2):
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Table 1. Patients' characteristics
Sex Il11l11uno-suppression
Number o] Age (years) Dl/ra/ion of dialysis
patients (mali/hs)
Male Female [muran + pred [muran +
pred.
+CSA
Total 29 2±8 21 8 7 ± 15 17 12
Group [ 17 9±7 12 5 16.1 ± 8.9 II 6
Group II 8 3±9 5 3 5 ± 17 6 2
Group III 4 36 ± 11.3 4 7 ± 29 4


































I. Serum TNF-a and its soluble receptors in
healthy controls and group I:
Values were 7.3 ± 1.6 vs 7.5 ± 4.6 pg/ml for TNF-
a, 5.9 ± 2.2 Vs 6.4 ± 4.7 ng/ml for TNF-SR55
and 8.9 ± 3.0 Vs 12.5 ± 8.0 ng/ml for TNF-SR75
respectively (P> 0.05).
Both groups showed insignificant difference in
the levels of TNF-a, SR55 and SR75 (Table 2),
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2. Serum TNF-a and its soluble receptors in ESRD:
In contrast to controls and group I, patients with
ESRD had elevated levels. TNF-a (26.3 ± 9.7)
ranged from 13.5 to 48.3 pg/ml, SR55 (28.2 ±
8.3) ranged from 12.4 to 45.1 ng/ml while SR75
(42.5 ± 11.1) ranged from 23.3 to 55.9 ng/ml
(Table 2).
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Table 2. Serum values of TNF-a and its soluble receptors in healthy controls, end stage renal failure (Pre- Tx) and in group I (day + 15
following Tx.)
During haemodialysis (Pre-Tx) (No. 29) Group / (No. /7)
Healthy controls (No. /0)
Pre- Tx (Day-I) P. value Day +15 P. value
post-Tx
TNF-a (pg/ml) 7.3 ± 1.6 26.3 ± 9.7 <0.01 7.5 ± 4.6 <0.05
(H.S.)* (N.S.)
TNF-SR55 5.9 ± 2.2 28.2 ± 8.3 <0.01 6.4 ± 4.7 >0.05
(ng/ml) (H.S.) (N.S.)
TNF-SR75 8.9 ± 3.0 42.5 ± 11.1 >0.01 12.5 ± 8.0 >0.05
(ng/ml) (H.S.) (N.S.)
HS = Highly significant *
3. Serum TNF-a and its soluble receptors in group
II:
In comparison to internal controls (during stable
allograft function), there was highly significant
increase of TNF-a and its solube receptors during
acute rejection episode: TNF-a (8.8 ± 3.8 Vs 37.2
± 16.2 pg/ml), SR55 (7.0 ± 4.3 Vs 16.9 ± 9.6
Table 3. Serum values ofTNF-a and its soluble receptors in group II.
ng/ml) and SR75 (16.1 ± 10.3 Vs 30.9 ± 13.4
ng/ml) (P < 0.01). A significant increase in levels
of TNF-a and soluble receptors was observed on
comparing values of internal controls to those of
the day R-2 (22.4 ± 13.7 pg/rnl, 13.8 ± 10.1 &
26.8 ± 11.6 ng/ml respectively P < 0.05) (Table
3).
HS = Highly significant ..
4. Serum TNF-a and its soluble receptors in group
III:
Compared to internal controls obtained during
clinically stable course in group III (Table 4),
there was insignificant decrease (P> 0.05) in the
levels of TNF-a during CSA nephrotoxicity (10.3
± 1.9 Vs 9.9 ± 2.1 pg/rnl) with highly significant
increases of SR55 and SR75 levels (5.5 ± 2.1 Vs
9.4 ± 1.0 and 12.4+4.8 Vs 21.2 ± 6.8 ng/ml
respectively) (P < 0.0 I).•
Table 4. Levels ofTNF-a and its soluble receptors in eSA nephrotoxicity group.
Stable function (internal During CS-A nephrotoxicity P value
controls)
TNF-a (pg/ml) 10.3±1.9 9.9 ±2.1 P < 0.05
(N.S.)'"*
TNF-SR55 5.5 ± 1.2 9.4± 1.0 P>O.OI
(ng/ml) (H.S.)*
TNF-SR75 12.4 ± 4.8 21.2 ± 6.8 P>O.OI
(ng/ml) (II.S.)*
HS = Highly significant *, NS = Insignificant **
5. Changes in the ratio of circulating TNF-a over
its receptors levels during renal allograft rejection
and CS-A nephrotoxicity (Table 5):
On calculating the ratios it was observed that both
ratios were significantly increased during acute
rejection episodes when compared to internal
Table 5. Ratios ofTNF-a and soluble TNF receptors
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controls (2.4 ± 0.6 Vs 1.4 ± 0.7 and 1.3 ± 0.5 Vs
0.7 ± 0.4; P < 0.01) and decreased insignificantly
during CSA nephrotoxicity in contrast to internal
controls (1.5 ± 0.5 Vs 2.0 ± 0.7 and O. 5 ± 0.3 Vs














TNF-a/SR55 1.5 ± 1.0 1.4 ± 0.7 1.8 ± 0.6 ±0.6 <0.01 2.0 ± 0.7 1.5 ± 0.5 >0.05
Drange (0.5-3.8) (0.7-2.1) (0.7-2.7) ( 1.1-3.4) (H.S.) (1.2-2.7) (0.8-1.3) (N.S.)**
*
TNF-a/SR75 0.7 ± 0.5 0.7 ± 0.4 0.8 ± 0.3 ±0.5 <0.01 0.9 ± 0.2 0.5 ± 0.3 >0,05
Drange (0.3-1.3) (0,2-1.5) (0.2-1.2) (0.6-2.2) (H.S.) (0.5-1.5) (0.3-0.8) (N.S.)**
*
liS = lIighly significant *, NS = lnsignificant **
Discussion
Renal allograft rejection involves several cytokines
which are produced by infiltrating T lymphocytes and
rnacrophages. TNF-a is responsible for the innam-
matory process as well as the local and systemic
manifestations during rejection. It also has cytolytic
activity and ability to stimulate immune competent
cells to produce interleukm-L The latter leads to an
enhanced interleukin-2 production by T cells [14].
TNF-a is an extremely pluripotent cytokine involved
in various immunological events [1,16]. It destroys
the graft tissue either directly or indirectly through
the release of other cytokines.
Two cellular TNF receptors have been clearly
distinguished: TNF-SR55 and TNF-SR75 [2,5]. If
TNF-a concentration increases, the surface receptors
will be upregulated. ConsequenLly many of these
surface receptors will loose their binding sites by
shedding the extracellular domain to body fluids such
as plasma, probably through proteolytic cleavage.
This released part is defined as soluble TNF receptor
[ 121. These soluble molecules in plasma are capable
of binding TNF with high affinity and specificity
[19]. Thus acting as a physiological irnrnuno-
regulatory mechanism for protecting the host against
the deleterious effects of TNF-a [20].
We observed high levels of TNF-a and its receptors
in ESRD. Levels ranged widely among patients and
an individual susceptibility is suspected.
Haemodialysis is known to induce release of TNF-a
[6] with subsequent release of its receptors. The
elevated TNF-a may reflect stimulation of circulating
mononuclear cells during the haemodialysis proce-
dure. Increased levels of soluble receptors could be a
retention phenomena from the chronic renal failure
per se or by an active cleavage· of the soluble
receptors from activated mononuclear cells which
may occur during haemodialysis [7]. The elevation of
TNF-a and its soluble receptors in our
haemodialysed patients is in agreement with previous
publications [7,14,3,18].
The serum TNF-a and its soluble receptors in our
study started to increase two days before the onset of
acute rejection (R-2) followed by increase of serum
creatinine on the day of rejection episode (RO).
Renal biopsy and creatinine are the bases for starting
anti-rejection therapy.
Therefore, it seems important to assess these
parameters as they will offer an early diagnosis of
rejection and planning for therapeutic strategy. Our
findings are consistent with that of Keil [II] and
Dorge [7].
During cyclosporine nephrotoxicity, our observations
revealed insignificant decrease in serum levels of
TNF-a whereas the levels of soluble inhibitory
receptors were increased. Our findings were similar
to the results of Dorge [7). Possible explanations for
such observations are: TNF-a is not affected by the
decline of kidney function [7] and CSA decreases
TNF-a release from mononuclear cells directly or
indirectly by blocking interleukin 2 release from
lymphocytes [9].
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The role of TNF-a and its soluble receptors in the
detection of allograft rejection versus eS-A nephro-
toxicity was reported by Dorge et al. [7] who
expressed TNF-a in relation to its soluble receptors.
They found that the ratios TNF-a to SRSS and SR75
decreased during eSA nephrotoxicity an~ were not
different during acute rejection episodes. However, in
our study, we detected a highly significant increase of
the ratios during rejection episodes and insignificant
decrease during eSA nephrotoxicity. These ratios
indicate the predominance of inhibitory soluble
receptor activity over proinflamrnatory TNF-a
activity during episodes of eS-nephrotoxicity but not
during acute rejection episodes [7]. Therefore, the
expression of TNF-a in relation to its naturally
occurring inhibitors provides a better parameter to
discriminate acute rejection episodes from cyclo-
sporine nephrotoxicity and suggests a pathophysiolo-
gical role of TNF-a in acute allograft rejection [7].
In the present study, we focused our work on
transplant recipients with well functioning grafts and
those with episodes of acute rejection or es-
nephrotoxicity. Further studies are suggested to
clarify the role of both TNF-a and its soluble
receptors in acute tubular necrosis, intercurrent
infection and during anti-rejection therapy.
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